Brazil vs Jordan: Average cost of multi drug-resistant tuberculosis treatment
Brazil
4,102 constant 2022 US$
in 2024
Jordan
5,124 constant 2022 US$
in 2024
Brazil rank
10th
Jordan rank
8th
Average cost of multi drug-resistant tuberculosis treatment over time
- Brazil
- Jordan
How they compare
Jordan currently reports 5,124 constant 2022 US$ against 4,102 constant 2022 US$ in Brazil, a difference of 1,022 constant 2022 US$.
That makes Jordan's figure about 1.2 times Brazil's.
The two have swapped places 3 times across 8 shared years of data; in 2017 it was Brazil ahead.
Brazil ranks 10th and Jordan ranks 8th of 92 countries.
Across the 2 decades both report, Brazil averaged higher in 1 and Jordan in 1.
Head to head by decade
| Decade | Brazil | Jordan | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 2,620 constant 2022 US$ | 12,250 constant 2022 US$ | 9,630 constant 2022 US$ | Jordan |
| 2020s | 4,011 constant 2022 US$ | 3,905 constant 2022 US$ | 106 constant 2022 US$ | Brazil |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Brazil or Jordan?
- Jordan, at 5,124 constant 2022 US$ against 4,102 constant 2022 US$ in Brazil as of 2024.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Brazil and Jordan?
- 1,022 constant 2022 US$, with Jordan ahead.
- How many years of comparable data are there for Brazil and Jordan?
- 8 years are reported by both, from 2017 to 2024.
- How do Brazil and Jordan rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Brazil ranks 10th and Jordan ranks 8th of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.